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Abstract 
Acute kidney injury (AKI) is a frequent complication of critical illness and carries a significant risk of short‑ and long‑
term mortality, chronic kidney disease (CKD) and cardiovascular events. The degree of renal recovery from AKI may 
substantially affect these long‑term endpoints. Therefore maximising recovery of renal function should be the goal 
of any AKI prevention and treatment strategy. Defining renal recovery is far from straightforward due in part to the 
limitations of the tests available to assess renal function. Here, we discuss common pitfalls in the evaluation of renal 
recovery and provide suggestions for improved assessment in the future. We review the epidemiology of renal recov‑
ery and of the association between AKI and the development of CKD. Finally, we stress the importance of post‑dis‑
charge follow‑up of AKI patients and make suggestions for its incorporation into clinical practice. Summary key points 
are that risk factors for non‑recovery of AKI are age, CKD, comorbidity, higher severity of AKI and acute disease scores. 
Second, AKI and CKD are mutually related and seem to have a common denominator. Third, despite its limitations full 
recovery of AKI may best be defined as the absence of AKI criteria, and partial recovery as a fall in AKI stage. Fourth, 
after an episode of AKI, serial follow‑up measurements of serum creatinine and proteinuria are warranted to diagnose 
renal impairment and prevent further progression. Measures to promote recovery are similar to those preventing 
renal harm. Specific interventions promoting repair are still experimental.
Keywords: Acute kidney injury, Acute kidney disease, Chronic kidney disease, Renal replacement therapy, Follow‑up, 
Biomarkers
Introduction: why focus on recovery?
While acute renal impairment is sometimes thought 
of as a relatively trivial insult defined purely by changes 
in serum creatinine, the introduction and subsequent 
acceptance of the concept of acute kidney injury (AKI) 
has gradually alerted critical care and nephrology clini-
cians to potential late complications in AKI survivors. It 
is well recognised that progressive or persistent impair-
ment in renal function may occur following an episode 
of AKI, with the potential to progress to end-stage kid-
ney disease (ESKD) with dialysis dependence. However, 
the outcome from an episode of AKI cannot simply be 
regarded as the binary administration for chronic renal 
replacement therapy (RRT) or recovery. Several authors 
have highlighted the substantial risk of development and 
progression of chronic kidney disease (CKD), short of 
ESKD [1–11] which is in turn strongly associated with 
increased short- and long-term mortality [10, 12]. This 
association does not necessarily implicate causation but 
could also indicate a common underlying disease process 
(Fig.  1). The question thus arises ‘What do we mean by 
renal recovery after AKI?’ Furthermore, in the absence 
of an effective therapy to alter the acute course of estab-
lished AKI, our current focus should be turned towards 
both AKI prevention and promotion of kidney repair in 
the recovery phase.
Pathophysiology of recovery
The mechanisms underlying the renal repair process after 
AKI have predominantly been studied in animal models 
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of ischaemic AKI, characterized by loss of the brush bor-
der, principally in the proximal tubular epithelium, with 
inflammatory cell infiltration and epithelial cell slough-
ing, followed by repopulation of the damaged tubules 
by regenerating cells. After much debate as to whether 
the cells involved in this regenerative process are endog-
enous tubular epithelial cells, adult renal stem cells or 
bone marrow-derived stem cells, there is now increasing 
evidence that the repopulation mainly relies on surviv-
ing endogenous tubular cells with bone marrow-derived 
stem cells having at most a paracrine role through growth 
factor secretion [2].
Under certain circumstances, renal repair is maladap-
tive with inflammation, fibrosis and vascular rarefac-
tion leading to persistent cell and tissue malfunction 
and eventually CKD. The frequency, severity, type and 
duration of injury as well the premorbid renal reserve 
(age, pre-existing CKD) seem to be risk factors for mal-
adaptive repair. Both injured tubular epithelial cells and 
macrophages play an important role in this maladaptive 
repair process. Perturbations of the cell cycle with arrest 
in the  G2 phase and tubular cells failing to differentiate 
lead to production of proinflammatory and profibrotic 
signals and proliferation of the resident fibroblast popu-
lation [2]. Whole organ gene expression profiling has 
been employed to identify molecular markers and regula-
tory pathways controlling the repair process [13] (Fig. 2). 
Understanding the mechanisms underlying maladaptive 
repair could potentially provide new targets for thera-
peutic intervention. In particular, strategies directed at 
inhibiting fibrosis or enhancing the endogenous repair 
processes may be promising.
Clinical definition of renal recovery
Pitfalls in evaluation of recovery
Assessment of baseline function
An adequate definition of renal recovery requires a relia-





Cardiovascular disease, AKI and ESRD 
Fig. 1 Complex interrelationship between cardiovascular disease, 
acute kidney injury (AKI) and chronic kidney disease (CKD) as risk 
factors for end‑stage renal disease (ESRD). High age, severe acute 
disease and possibly the modality of renal replacement therapy in 
patients with positive fluid balance are additional risk factors for 
progression to ESKD
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Fig. 2 Pathophysiology of recovery
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non-recovery from pre-existing CKD. Efforts to obtain 
baseline kidney function, e.g. from the primary care or 
referring specialists, are therefore of utmost importance. 
The mean outpatient serum creatinine (SCr) (and the 
derived estimated glomerular filtration rate, eGFR) or, 
failing this, the most recent SCr measured between 7 and 
365 days prior to the start of the acute illness is generally 
considered the best reflection of baseline kidney function 
[14]. Extremes in muscle mass or dietary protein intake 
may affect SCr independent of kidney function. Although 
use of cystatin C and cystatin-based eGFR equations may 
reduce this problem [15], a baseline cystatin  C level is 
rarely available. Another potential shortcoming of SCr, 
and the derived eGFR, is insensitivity to detect mild 
underlying CKD and the inability to detect the pre-exist-
ing presence or absence of renal functional reserve [16].
In the absence of a known baseline SCr the Kidney 
Diseases Improving Global outcomes (KDIGO) AKI 
workgroup suggests estimation of baseline through use 
of the Modification of Diet in Renal Disease (MDRD) 
equation [17]. This estimation assumes that patients have 
a baseline eGFR of 75  mL/min/1.73  m2, does not allow 
one to detect the presence of pre-existing CKD or well-
preserved renal function and will undoubtedly confound 
the evaluation of recovery [18]. In addition, the absence 
of a baseline SCr is usually non-random as demonstrated 
in a recent analysis which found less complete recovery 
in patients with unknown or missing baseline SCr com-
pared with those with a known baseline [19]. An alterna-
tive is to use admission creatinine as a baseline. However, 
this ignores pre-admission AKI and has many other 
potential confounders including the absence of steady 
state, the effect of dilution after fluid resuscitation and 
reduced creatinine production in critical illness [20].
Defining the population
While most studies on renal recovery exclude prior ESKD 
(as defined by need for chronic dialysis), the handling of 
pre-existing CKD is variable. Furthermore, recovery has 
been reported in different populations (hospitalized ver-
sus ICU patients, general ICU versus specific surgical or 
medical populations, inclusion or exclusion of less severe 
forms of AKI). Whether recovery should be evaluated 
in all AKI patients or in survivors only depends on the 
setting. In a clinical trial evaluating an intervention to 
improve recovery, mortality should be treated as a com-
peting endpoint. However, recovery in survivors may also 
be relevant to assess at the bedside [19].
Timing of recovery assessment
In the current literature, the timing for the evaluation of 
renal recovery varies considerably. Some studies deter-
mine “recovery” after 3–7  days to make the distinction 
between transient and persistent AKI. Recent evidence 
suggests that the time pattern of changes in kidney 
function and relapses after initial “reversal” may also be 
associated with mortality [12, 21]. Most studies report 
recovery at hospital discharge. However, its evaluation at 
a fixed time point, e.g. at 3 months, allowing one to mark 
the transition from AKI to CKD, would be more appro-
priate. Delaying the assessment might also reduce the 
problem of the impact of sarcopenia on SCr levels. The 
recent Acute Disease Quality Initiative (ADQI) confer-
ence suggests differentiating AKI (first 7 days) from acute 
kidney disease (AKD) (AKI persisting for 7–90 days) and 
CKD (after 90 days), which may provide a framework for 
defining recovery in terms of time after the sentinel event 
(Fig. 3). While AKD was initially proposed to encompass 
any acute condition that impacts on longer-term kidney 
function [22], this more recent ADQI proposal further 
refines the criteria with the addition of a staging system 
[23].
Defining recovery
In the past, renal recovery was often defined as independ-
ence from RRT following dialysis-requiring AKI. More 
recently, non-recovery from less severe AKI has received 
more attention due to its association with adverse long-
term outcomes [1, 21]. Despite many limitations the 
most obvious definition of full recovery from AKI is the 
absence of AKI criteria. Partial recovery can then be 
defined as a fall in AKI stage. Recovery may occur early 
after the insult leading to AKI or later during the phase of 
AKD (Fig. 3). However, it is important to appreciate that 
the use of the creatinine criteria may result in important 
underestimation of recovery in patients with unknown 
premorbid creatinine [18] or overestimation of recovery 
by ignoring the loss of muscle mass that occurs during 
critical illness [19, 24]. Tubular secretion of creatinine, 
the contribution of which increases with decreasing GFR, 
also results in overestimation of GFR by creatinine clear-
ance. An alternative definition of non-recovery might be 
the presence of eGFR criteria for new or worsening CKD 
[25], which, however, still relies on SCr with its associ-
ated shortcomings.
Future directions
An ideal definition of recovery would compare the gold 
standard of GFR measurement before and after the epi-
sode of AKI. Even better would be the inclusion of an 
assessment of renal functional reserve before and after 
the episode of AKI. However, outside predictable events 
such as elective major surgery, accrual of such data is 
highly unlikely. Despite this, there are potential avenues 




A potential avenue for exploration is the determination of 
the measured creatinine clearance at ICU discharge from 
a timed urinary collection coupled with a serum creati-
nine determination. Such an estimate of GFR is not with-
out its detractors but is readily available and economical. 
Since premorbid creatinine clearance will usually not be 
available, defining recovery by this parameter assumes 
that the estimation of premorbid GFR with predictive 
equations is reliable and does not account for overesti-
mation of glomerular filtration by creatinine clearance 
due to tubular creatinine excretion [19]. However, meas-
uring creatinine clearance at ICU or hospital discharge 
may serve as a baseline for the follow-up.
Measurement of renal functional reserve
Renal functional reserve is defined as the increase in 
GFR after a stress test (e.g. an acute protein load [26]). Its 
measurement is difficult to perform in the ICU and few, 
if any, patients have such data available prior to an AKI 
event. However, assessing renal reserve could be useful to 
identify patients who are at increased risk of further pro-
gressive CKD or recurrent AKI (Table 1).
Kinetic eGFR
Kinetic eGFR is a mathematical method to estimate 
underlying renal function from the rate of change of 
creatinine during non-steady state conditions and has 
been proposed for the earlier detection of changes in 
GFR, both during development and recovery of AKI 
[27, 28]. However, in the critically ill there are sev-
eral potential confounders that affect measured SCr 
concentrations and the eGFR, including assumptions 
regarding maximal rise in creatinine, reductions in 
creatinine production and changes in the volume of 
distribution. Although in comparison with novel AKI 
biomarkers, this technique has been shown to perform 
as well or better in predicting short-term recovery of 
kidney function (within 48 h) [28], the assumption that 
muscle mass is constant makes it less useful in assessing 
kidney function including recovery over a longer time-
period in ICU patients. Measurement and correction 
of kinetic eGFR for muscle mass loss may be a way of 
improving this method.
Real‑time GFR monitoring
Real-time GFR monitoring techniques are still experi-
mental [29, 30], but nearing clinical implementation. The 
development of such systems will clearly aid in identify-
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Up to 7 Days Post Injury 7-90 Days Post Injury >90 Days Post Injury
Fig. 3 AKI, AKD, CKD and time course of recovery. Recovery may occur early during acute kidney injury (AKI) up to 7 days after the insult, or later 
during acute kidney disease (AKD), between 7 days and 3 months after the insult to the kidney
Table 1 Risk factors for  short-term non-recovery of  renal 
function
AKI acute kidney injury, KDIGO kidney disease improving global outcomes





Severity of acute disease High illness severity
Haemodynamic instability
Medical admission
Severity of AKI Higher KDIGO stage
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Biomarkers for (non)recovery
The limitations of both SCr and urine output as early 
indicators of AKI are well documented and have led to 
the pursuit of robust early markers of kidney damage. 
These biomarkers can be broadly classified as inflamma-
tory biomarkers [e.g. neutrophil gelatinase-associated 
lipocalin (NGAL), interleukin (IL)-6 and IL-18], cell 
injury biomarkers [e.g. kidney injury molecule-1 (KIM-1) 
and liver fatty acid binding protein (L-FABP)] and mark-
ers of cell cycle arrest [e.g. insulin growth factor binding 
protein 7 (IGFBP7) and tissue inhibitor of metallopro-
teinase 2 (TIMP-2)] (Table 2).
Few studies have evaluated these classical injury 
markers for their ability to predict recovery. Currently, 
NGAL has received most attention in this context. 
Plasma NGAL, measured on the first day of AKI stage 
3, has been shown to be a reasonable predictor of fail-
ure to recover in a cohort of patients with community-
acquired pneumonia, many of whom were not in the 
ICU [32]. A small substudy of the VA/NIH Acute Renal 
Failure Trial Network Study found that, in addition to 
age and a high Charlson comorbidity index, higher con-
centrations of a panel of urinary biomarkers at day 14 
after commencement of RRT may improve the predic-
tion of non-recovery/dialysis dependence at 60  days 
[33]. However, the investigators used a combined end-
point of death or renal non-recovery and only had 25 
deaths and 13 non-recovery patients. Similarly, a panel 
of biomarkers applied to patients with AKI requiring 
RRT demonstrated that decreasing urinary NGAL dur-
ing the first 14 days following AKI was associated with 
a reduced need for renal support at 60  days [34]. This 
study clearly highlights the value of repeated meas-
ures over single values. KIM-1 and L-FABP have also 
been proposed as a marker of renal recovery after AKI 
[35, 36]. Similarly the product of the more recently 
described  G1 cell cycle arrest markers of renal stress 
TIMP-2 and IGFBP7 ([TIMP-2] × [IGFBP7]) predicted 
short-term renal recovery/non-recovery within 48 h in 
57 patients with early AKI [37].
Table 2 Biomarkers of short-term acute kidney injury (AKI) recovery versus persistence to acute kidney disease (AKD)
Relevant references are mentioned in the text
AKI acute kidney injury, CRS cardiorenal syndrome, DGF delayed graft function, ICU intensive care unit, IGFBP-7 insulin-like growth factor binding protein 7, IL-18 
interleukin 18, L-FABP liver-type fatty acid-binding protein, KIM-1 kidney injury molecule-1, NAG N-acetyl-β-d-glucosaminidase, NGAL neutrophil gelatinase-associated 
lipocalin, TIMP-2 tissue metalloproteinase 2, RRT renal replacement therapy, kDa kilodalton
AKI biomarker Characteristics Clinical setting Outcome




Cystatin C 13 kDa cysteine protease inhibitor produced by all nucleated human cells; under‑
goes glomerular filtration
ICU RRT










IL‑18 18 kDa pro‑inflammatory cytokine; regulates innate and adaptive immunity; 








KIM‑1 39 kDa transmembrane glycoprotein involved in tubular regeneration; released 







L‑FABP 14 kDa intracellular lipid chaperone produced in proximal tubular cells; aids in 






MicroRNA Endogenous single‑stranded molecules of non‑coding nucleotides; upregulated 






NAG >130 kDa lysosomal enzyme; produced in proximal and distal tubular cells; 
released into urine after tubular cell injury
Hospitalised patients RRT
NGAL At least three different types:
  Monomeric 25 kDa glycoprotein produced by neutrophils and epithelial cells, 
including renal tubules
  Homodimeric 45 kDa protein produced by neutrophils
  Heterodimeric 135 kDa protein produced by renal tubular cells released into 









Even less data is available on biomarkers that are 
specific for the repair process. In the setting of CKD, 
transforming growth factor beta (TGFβ), monocyte 
chemoattractant protein-1 (MCP-1) and matrix metal-
loproteinase protein-2 (MMP-2) have been shown to 
correlate with fibrosis and CKD progression [38]. After 
renal transplantation, urinary YKL-40, a repair phase 
protein, in the donor is independently associated with 
recovery from AKI and delayed graft function [39]. Dip-
stick albuminuria greater than 30 mg/dL is independently 
associated with lower rates of AKI recovery at 30 days in 
patients with sepsis [40]. Another promising biomarker 
for recovery is osteopontin [41, 42].
In general, trials evaluating biomarkers for prediction 
of recovery after AKI have been small and focussed pre-
dominantly on the differentiation between transient AKI 
and AKD.
Identification and Validation of Biomarkers of Acute 
Kidney Injury Recovery (ClinicalTrials.gov Identifier: 
NCT01868724) was a multicentre study to validate bio-
markers specifically for major adverse kidney event 
(MAKE) and major adverse cardiac events (MACE) fol-
lowing an episode of AKI in ICU. The results are still 
awaited. Hopefully, the increasing insights into the 
molecular mechanisms of renal recovery will lead to new 
biomarkers specific to the repair process.
Potential markers of tubular function
One area that has received little attention in the post 
AKI period is that of tubular function. In CKD, proteinu-
ria is the best predictor of both disease progression and 
ESKD over and above hypertension [43] which may arise 
because of both increased glomerular permeability and 
reduced tubular uptake of filtered protein. A few studies 
have highlighted that patients with preoperative protein-
uria are at increased risk of AKI particularly after cardiac 
surgery [44, 45] and after severe burns [46]. Moreover, 
(tubular) proteinuria has been found to be associated 
with worse outcomes in the critically ill including the rate 
of AKI and long-term kidney function [47–49]. Other 
markers of tubular function have not been studied in any 
detail. Since proteinuria is known to be a modifiable risk 
factor in CKD, such assessment should be mandated in 
the follow-up of patients with AKI.
Epidemiology of renal outcome after AKI
Short‑term renal outcome
Rates of non-recovery from dialysis-requiring AKI differ 
dramatically among populations and can vary between 
0% and 40% [12, 50]. Differences in the indications and 
thresholds for starting RRT may account for some vari-
ability. Other studies have evaluated recovery from all 
AKI (including less severe forms) and reported complete 
recovery rates between 33% and 90% [12, 19, 32, 51–57]. 
However, the use of different definitions of AKI (with or 
without inclusion of the urine output criteria, with inclu-
sion or exclusion of less severe forms), different defini-
tions of recovery, the variable case-mix (surgical, medical 
or mixed population, inclusion or exclusion of patients 
with CKD, evaluation in survivors only) and differences 
in timing of assessment of recovery prevent a direct com-
parison of the results. Last, inclusion of patients dying 
during ICU stay strongly affects recovery rate, recovery 
being a time-dependent process and death during ICU 
stay acting as a potent confounder [19].
Long‑term renal outcome
The association between AKI and subsequent progres-
sion to CKD has been highlighted by recent epidemiolog-
ical studies [1, 3, 5, 6, 10, 21, 34, 58–62], although a causal 
relation cannot be proven. The association between AKI 
and CKD is complex and multidirectional so that CKD 
evolution may be either through non-recovery from AKI, 
de-novo development of CKD after recovery from AKI 
or progression of pre-existing CKD. In patients without 
prior CKD who have complete recovery of renal function, 
the risk of progressive CKD may be low [63]. However 
other authors have demonstrated a substantial incidence 
of de novo CKD and death in survivors of AKI, including 
those who do not require RRT [60].
As outlined, most studies demonstrate that the risk 
for ESKD after AKI is increased (Table 3) [10, 62]. Most 
studies on long-term kidney outcome are limited to 
patients receiving RRT and suggest that dialysis depend-
ency at 90 days may approach up to 30% [10, 11, 50, 64, 
65]. A large Danish registry study comprising 3062 ICU 
patients treated with RRT (among a total of 107,937 ICU 
patients) suggested a 5-year cumulative risk of ESKD of 
11.7% (95% CI 10.5–13.0) [6]—in keeping with a Swedish 
registry study comprising 998 RRT-treated AKI patients 
[66]. The Danish registry study [6] revealed an adjusted 
HR of 105 (95% CI 78–142) for ESKD at 180  days for 
RRT-treated AKI patients compared to other criti-
cally ill patients (Table  3). The absolute risk difference 
was highest among those RRT-AKI patients with pre-
existing CKD, and the relative risk of ESKD was highest 
among younger RRT-AKI patients, those with previous 
CKD, and those with elective surgery. Death and chronic 
dialysis treatment are competing risks which should be 
included in the analysis [67]. The follow-up study by the 
RENAL investigators [65] showed that the risk of dying 
was much greater than the risk of ESKD.
Risk factors/predictors for non‑recovery
Risk factors for non-recovery after AKI include age, 
comorbidity, severity of acute disease and potentially the 
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modality of RRT [64, 68]. Among patient-related risk fac-
tors for non-recovery, high age [4, 12, 33, 61], the pres-
ence of CKD [8, 12, 34, 61, 69] and comorbidities such as 
hypertension, diabetes mellitus and cardiac disease [12, 
33, 50] are the most frequently reported hazards. The 
common denominator is diminished glomerular reserve 
associated with age or chronic disease, suggesting a com-
mon underlying disease causing AKI and CKD. Type 
and severity of the acute disease process may also deter-
mine non-recovery. A high acuity of illness as reflected 
by higher APACHE or SAPS scores [12, 70, 71], a higher 
degree of haemodynamic instability [12, 34, 72], medi-
cal admission [12] or more severe AKI [12, 59, 73, 74] are 
additional risk factors for non-recovery. Interestingly, the 
evidence associating sepsis diagnosis with renal recov-
ery after AKI is conflicting [12, 58]. In summary, putative 
mechanisms predisposing to renal non-recovery are expo-
sure of a relatively decreased nephron mass to greater 
injury coupled with impaired or maladaptive repair mech-
anisms associated with age or chronic disease.
In general, patients needing RRT have a higher mor-
tality and risk of non-recovery [64, 71, 75, 76]. Whereas 
some data suggest that RRT may be independently 
associated with impaired recovery following AKI [75], 
this issue remains controversial because of numerous 
unmeasured confounding variables. The impact of RRT 
modality on recovery remains controversial, too. While 
retrospective cohort studies suggest that initial use of 
CRRT is associated with less CKD than intermittent hae-
modialysis [64, 66], not all studies support this notion 
[77]. A meta-analysis showed that the benefit of CRRT 
was based on results in observational studies but not 
randomised controlled trials (RCTs) [68]. Interestingly, 
a recent retrospective observational French study used 
marginal structural modelling and found no differences 
in 30-day mortality and dialysis dependence (combined 
primary outcome) between continuous and intermit-
tent RRT in the overall population. However, continu-
ous treatment was associated with better 30-day survival 
without dialysis in patients with fluid overload, while it 
was associated with worse outcome in patients without 
haemodynamic instability at commencement of RRT 
[78]. Another recent multicentre retrospective cohort 
evaluating 638 patients alive at hospital discharge could 
not demonstrate any difference in renal recovery after 
adjustment for covariates between patients treated with 
intermittent haemodialysis or continuous RRT [77]. The 
authors suggest that when initial RRT modality is chosen 
primarily on haemodynamics, renal recovery in survivors 
is comparable between both modalities. Altogether, risk 
factors for non-recovery of AKI are higher age, CKD, 
comorbidity, higher severity of AKI and acute disease 
scores, while intermittent haemodialysis seems to be 
associated with non-recovery in patients with fluid over-
load at commencement of RRT.
Potential measures to promote renal recovery
General measures aimed at preventing AKI and protect-
ing the kidney function should increase the chances for 
recovery [22, 23, 79]. This includes avoiding hyperglycae-
mia and nephrotoxins as well as using strict therapeutic 
drug monitoring if applicable. Episodes of renal hypoper-
fusion should be avoided by ensuring haemodynamic sta-
bility and adapting RRT modality to the haemodynamic 
situation and the presence of fluid overload [77, 78]. Spe-
cific interventions to promote recovery are still experi-
mental. Promotion of cell proliferation and renal repair by 
clusterin [80, 81] and/or reducing post-injury fibrosis by 
AT1 receptor antagonism [82], pyridoxamine [83], alpha 
klotho [84], endothelial sphingosine-1-phosphate recep-
tor 1 [85] or PTBA analogues [83] are some approaches 
that have shown promising results in animal studies.
Follow-up of AKI patients
Which patients require follow‑up?
Follow-up for development of CKD should be consid-
ered in all patients who developed AKI, irrespective of 
the apparent degree of renal recovery. Importantly, while 
only a small proportion of AKI survivors may develop 
ESKD over time, many instead die, especially from cardi-
ovascular causes [86]. CKD is indeed strongly associated 
with cardiovascular morbidity and mortality [87, 88]. In 
Table 3 Long-term risk of end-stage kidney disease (ESKD) after acute kidney injury (AKI) and renal replacement therapy 
(RRT) treated AKI
HR hazard ratio, CI confidence interval
AKI stage Absolute risk (%)/at time Hazard ratio, HR (95% CI) over time
AKI (all stages) vs. non‑AKI 2% vs. 0.08%/1 year [62]
3.9% vs. 0.3%/5 year
HR 3.1 (1.9–5.0) per 100 patient‑years [10]
RRT‑treated AKI 90 days: 30% [10, 11, 50], 25% [64], 5.4% [65]
180 days: 8.5% [6]
1 year: 20% [64]
5 years: 11.7% (cumulative risk) [6]
7 years: 3.4% (new ESKD) [66]
Up to 180 days: HR 105 (78–148) vs. critically ill [6]
From 80 days to 5 years: HR 6.2(4.7–8.1) vs. critically ill [6]
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younger survivors, development of hypertension and car-
diovascular disease may accelerate CKD progression, so 
that ESKD may develop after many years even if there is 
an apparently good initial recovery. Thus, in all groups of 
AKI survivors there is great potential for interventions to 
improve longer-term outcomes.
How to organize follow‑up?
In practice the main hurdle is identifying patients for 
follow-up. This can be problematic as hospital discharge 
may be many weeks or months following the episode 
of AKI with the discharging team often not involved in 
the active management of the patient during their criti-
cal illness. Currently only a minority of patients who 
require RRT in the ICU and recover renal function 
receive nephrology follow-up [89, 90], illustrating the 
need to establish robust mechanisms to ensure targeted 
AKI follow-up. Such services have been developed and 
piloted [91, 92], but generally remain dependent on refer-
ral of patients following inpatient nephrology consulta-
tion, emphasising the need for appropriate involvement 
of renal services as inpatients to allow appropriately tar-
geted follow-up. Care pathways for follow-up should vary 
according to need. Patients with significant overt renal 
impairment at hospital discharge (e.g. eGFR  less than 
30  mL/min/m2) require reassessment of renal function, 
probably within 2  weeks of discharge. In others, reas-
sessment of renal function at 90 days after insult is more 
appropriate, to allow time for both recovery of muscle 
mass and any further recovery of renal function, permit-
ting a clearer assessment of the new baseline renal func-
tion (Fig.  4). Timing and location of follow-up will be 
Fig. 4 Potential scheme for follow‑up of acute kidney injury (AKI) stages 2–3 complicating critical illness. Potential scheme for follow‑up of acute 
kidney injury (AKI) stages 2–3 complicating critical illness. Serial assessments at 3 months and 1 year after AKI are required to establish the presence 
and severity of chronic kidney disease (CKD) and establish prognosis. In most cases, long‑term follow‑up and treatment can be achieved outside of 
specialist nephrology services following CKD management guidelines
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dependent on local resources; however, it is likely to be 
impracticable for all stage 1 AKI to receive follow-up in 
secondary care. Effective long-term management of CKD 
can be achieved in primary care, but this is only possi-
ble if patients are identified at discharge and appropriate 
clinical guidelines are provided by specialists.
Survivors of severe AKI requiring RRT and those with 
more advanced CKD may specifically benefit from spe-
cialist nephrology review [93]. Even at 3 months, creati-
nine may not accurately reflect GFR in many survivors of 
critical illness. Measurement of serum cystatin C, urinary 
creatinine clearance or even, theoretically, formal meas-
urement of GFR may be required in patients with signifi-
cant loss of muscle mass. Besides measurement of GFR, 
CKD assessment requires an assessment of proteinuria 
(urinary protein-to-creatinine ratio). Proteinuria, a com-
mon outcome after AKI even in the absence of overt 
renal dysfunction [94], potentially indicates underlying 
hyperfiltration and loss of renal reserve; however, irre-
spective of the underlying mechanism, its clinical impor-
tance is clear as proteinuria is very strongly associated 
with cardiovascular risk and progression of CKD at all 
levels of GFR [87, 88].
Even in the absence of evidence of CKD at 90 days, sur-
vivors of significant AKI should have at least one further 
check for CKD criteria at 1 year to check for late progres-
sion. A recent single-centre study examined patients who 
had eGFR greater than 60 mL/min/1.73 m2 12 months or 
later after an episode of dialysis-treated AKI with a pri-
mary outcome of time to CKD as defined by eGFR persis-
tently less than 60 mL/min/1.73 m2 [95]. Interestingly, in 
this cohort few patients with no CKD criteria function at 
1 year developed CKD over a median 9 years of follow-up. 
In those who did risk factors for the development of long-
term renal impairment consisted of older age, diabetes 
and known vascular disease. Thus, it may be reasonable 
to assume that AKI survivors without CKD at 1 year after 
illness are at low risk in the absence of other risk factors.
As the long-term ill effects of AKI are partially medi-
ated through the development of CKD the management 
of these patients should follow general current well-devel-
oped clinical CKD guidelines [96]. Treatment of hyper-
tension and modification of cardiovascular risk factors 
are central to management of patients with or at risk of 
CKD. In patients with diabetes or proteinuria, angioten-
sin converting enzyme (ACE) inhibitors or angiotensin-2 
receptor blocking agents should be first-line drugs for 
hypertension, as these may reduce proteinuria and the 
rate of progression of CKD [97]. However, recurrent epi-
sodes of AKI are a concern, and any follow-up programme 
should address the prevention and early detection of new 
episodes of AKI, including the need for early assessment 
with new acute illness and advice regarding the avoidance 
of nephrotoxin exposure and adjustment of regular medi-
cation in the setting of illness [98].
Conclusion
The acceptance of a unifying definition of AKI has 
increased awareness of the syndrome and generated 
much knowledge on morbidity and outcome. Less 
attention has been given to recovery from AKI. Despite 
many limitations, non-recovery of AKI is best defined 
as the presence of AKI criteria, and partial recovery as 
a fall in AKI stage. Both are associated with the devel-
opment of CKD and cardiovascular diseases, need of 
chronic dialysis and mortality. The incidence of non-
recovery differs between studies and populations. Risk 
factors include high age, CKD, comorbidity, higher 
severity of AKI and acute disease. After an episode of 
AKI serial follow-up measurements of serum creatinine 
and proteinuria are warranted to diagnose progressive 
renal impairment and implement measures to manage 
CKD if necessary.
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